Predictors of Ustekinumab Failure in Crohn's Disease After Dose Intensification.

ABSTRACT:

Background

Many patients with Crohn's disease (CD) who lose response to the standard ustekinumab dose interval of every 8 weeks (q8w) undergo dose intensification to q4w or q6w. However, baseline factors that predict success or failure after dose intensification are unknown. We sought to identify predictors of failure of ustekinumab after dose intensification for patients with CD.

Methods

This was a retrospective cohort study of adult CD patients undergoing ustekinumab dose intensification at a tertiary referral center between January 1, 2016, and January 31, 2019. Electronic health records were reviewed to obtain patient demographics, CD history, and laboratory data. The primary outcome was failure to achieve corticosteroid-free remission (Harvey-Bradshaw Index <5) within 1

SUBMITTER: Dalal RS 

PROVIDER: S-EPMC8314105 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature